An encouraging avenue for CAR-T therapy in pHGGs involves B7-H3 CAR-T, targeting B7-H3, an immune checkpoint molecule with high expression in tumor tissue and low presence in normal tissue. The gene discussed is CD276; the disease is neoplasm.